Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Clinical Oncology

• Publication date

  2009-09-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2008.21.3991PMID 19652063
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Follicular lymphoma in the United States: first report of the national LymphoCare study.

  2009cited by this paper
• Beta 2-microglobulin in chronic lymphocytic leukaemia.

  2009cited by this paper
• Investigation about a screening step in model selection

  2008cited by this paper
• Revalidation of FLIPI in patients with follicular lymphoma (FL) registered in the F2 study and treated upfront with immunochemotherapy

  2007cited by this paper
• Prognostic relevance of serum β2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study

  2007cited by this paper
• Revised response criteria for malignant lymphoma.

  2007cited by this paper
• Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

  2006cited by this paper
• The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect

  2006cited by this paper
• Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment.

  2005cited by this paper
• Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

  2005cited by this paper
• CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

  2005cited by this paper
• Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors

  2005cited by this paper
• Follicular lymphoma international prognostic index.

  2004cited by this paper
• Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.

  2004cited by this paper
• Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.

  2004cited by this paper
• Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.

  2003cited by this paper
• An elevated serum beta‐2‐microglobulin level is an adverse prognostic factor for overall survival in patients with early‐stage Hodgkin disease

  2002cited by this paper
• A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma.

  2001cited by this paper
• Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi.

  2000cited by this paper
• A strategy for modelling the effect of a continuous covariate in medicine and epidemiology.

  2000cited by this paper
• Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte.

  1999cited by this paper
• Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

  1999cited by this paper
• The clinical significance of molecular response in indolent follicular lymphomas.

  1998cited by this paper
• Natural history of and therapy for the indolent non-Hodgkin's lymphomas.

  1993cited by this paper
• Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model.

  1991cited by this paper
• Prognostic value of serum beta-2 microglobulin in low-grade lymphoma.

  1991cited by this paper
• The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party.

  1991cited by this paper
• Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years.

  1991cited by this paper
• Prognostic Value of Serum β-2 Microglobulin in Low-Grade Lymphoma

  1991cited by this paper
• Original article: The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma

  1991cited by this paper
• The significance of bone marrow involvement in non-Hodgkin's lymphoma: the Eastern Cooperative Oncology Group experience.

  1986cited by this paper
• Regression modelling strategies for improved prognostic prediction.

  1984cited by this paper
• Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.

  1983cited by this paper
• Evaluating the yield of medical tests.

  1982cited by this paper
• Serum beta 2 microglobulin and its prognostic value in lymphomas.

  1979cited by this paper
• Serum β2 microglobulin and its prognostic value in lymphomas

  1979cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• SOHO State of the Art Updates and Next Questions: How Should We Risk Stratify and Tailor Therapy for Patients With High Tumor Burden Follicular Lymphoma? A Systematic Review.

  2026cites this paper
• Hypogammaglobulinemia at leukapheresis predicts delayed humoral immune reconstitution and increased risk of infections after CD19 CAR-T for B-cell lymphoma.

  2026cites this paper
• Surveillance Strategies in Follicular Non-Hodgkin's Lymphoma's Using Molecular and Genetic Markers Improve Cost-efficiencies Over Routine Imaging Studies.

  2026cites this paper
• Metabolic Bulk Volume is an independent prognostic factor and facilitates identifying high risk cases for DLBCL patients treated with the R-CHOP.

  2026cites this paper
• Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025

  2026cites this paper
• Prognostic significance of Ki-67 in grade 3A follicular lymphoma and development of a novel PFS nomogram

  2026cites this paper
• Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma

  2025cites this paper
• A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma

  2025cites this paper
• The Predictive Role of Baseline 18F-FDG PET/CT Radiomics in Follicular Lymphoma on Watchful Waiting: A Preliminary Study

  2025cites this paper
• Clinical characteristics and molecular heterogeneity in Follicular lymphoma with extranodal involvement

  2025cites this paper
• Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408

  2025cites this paper
• Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi

  2025cites this paper
• Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review

  2025cites this paper
• The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma

  2025cites this paper
• Rethinking bone marrow biopsy: is PET/CT enough for staging low-grade follicular lymphomas?

  2025cites this paper
• Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects

  2025cites this paper
• Challenges in predicting outcomes for watch and wait follicular lymphoma patients: insights into clinical, pathological, and molecular factors

  2025cites this paper
• Clinical features and outcomes of primary ocular adnexal follicular lymphoma: a retrospective analysis

  2025cites this paper
• Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial

  2025cites this paper
• Curability Potential of Low-Grade Follicular Lymphoma.

  2025cites this paper
• Chemotherapy‐Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune‐Based Approaches

  2025cites this paper
• One for the ages: impact of age on international prognostic indices in lymphoid cancer

  2025cites this paper
• Tumor Microenvironment, Inflammation, and Inflammatory Prognostic Indices in Diffuse Large B-Cell Lymphomas: A Narrative Review

  2025cites this paper
• A Novel Age-Based Nomogram as the Best Predictor for Long-Term Overall Survival in Head and Neck Mucosa-Associated Lymphoid Tissue Lymphoma

  2025cites this paper
• Advances in Personalized Treatment and Prognostic Factors of Follicular Lymphoma

  2025cites this paper
• Follicular lymphoma: contemporary clinical management with a focus on recent therapeutic advances

  2025influential citation
• Frontline treatment of follicular lymphoma: What will it take to change current practice?

  2025cites this paper
• The age-adjusted international prognostic index 2 (A-FLIPI2) for elderly patients with follicular lymphoma

  2025cites this paper
• Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review

  2025cites this paper
• Deep immunophenotypic dissection and clinical impact of T cells in the follicular lymphoma microenvironment

  2025cites this paper
• Prognostic Role of Beta‐2 Microglobulin in Diffuse Large B‐Cell Lymphoma: Systematic Review and Meta‐Analysis of Observational Studies

  2025cites this paper
• Follicular lymphoma grade 3A: aggressiveness and curability in an Asian cohort of 781 patients

  2025cites this paper
• Exploratory Study to Evaluate the Impact of Interim PET/CT Assessment in First-Line Follicular Lymphoma

  2025cites this paper
• Lymphoma B cells remodel bone marrow stromal cells into extracellular matrix–producing cancer-associated fibroblasts

  2025cites this paper
• Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?

  2025cites this paper
• Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.

  2025cites this paper
• FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.

  2025cites this paper
• A Novel Prognostic Model for Primary CNS Lymphoma Incorporating Clinico-Laboratory Parameters.

  2025cites this paper
• A Phase I Trial of Evorpacept, Lenalidomide and Rituximab for Patients with B-cell Non-Hodgkin Lymphoma.

  2025cites this paper
• Erratum: Integration of PET/CT parameters and a clinical variable to predict the risk of progression of disease within 24 months (POD24) in follicular lymphoma

  2025influential citation
• Identifying high-risk patients with MALT lymphoma undergoing first-line therapy for disease progression

  2025cites this paper
• Treatment of Relapsed and Refractory Follicular Lymphoma: Which Treatment for Which Patient for Which Line of Therapy?

  2025cites this paper
• The Future of Follicular Lymphoma Management: Strategies on the Horizon.

  2025cites this paper
• Prognostic Value of 18F-FDG PET/CT Parameters at Baseline and End of Treatment in Follicular Lymphoma: A Systematic Review and Meta-analysis.

  2025cites this paper
• A folliculáris lymphoma ellátásának helyzete Magyarországon 2025-ben

  2025cites this paper
• Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma

  2025influential citation
• Integration of gene mutations in risk prognostication for watch‐and‐wait follicular lymphoma patients initiating first‐line treatment

  2025cites this paper
• JSH practical guidelines for hematological malignancies, 2023: II. lymphoma—overview

  2025cites this paper
• A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma

  2025cites this paper
• Polypharmacy independently predicts survival, hospitalization, and infections in patients with lymphoid cancer

  2025influential citation
• Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective

  2025cites this paper
• Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub‐Study of the FOLL12 Trial

  2025cites this paper
• Prognostication of Follicular Lymphoma: A Review of Prognostic Scores and Factors

  2025influential citation
• Obinutuzumab maintenance versus observation for patients with newly diagnosed high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy: a multicenter, randomized, phase III study (JCOG2008, MAIN study)

  2025cites this paper
• Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203

  2024cites this paper
• Prognostic value of the combination of volume, massiveness and fragmentation parameters measured on baseline FDG pet in high-burden follicular lymphoma

  2024cites this paper
• Lenalidomide, rituximab (R2), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma

  2024cites this paper
• End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial

  2024cites this paper
• The clinical significance and prognostic value of serum beta-2 microglobulin in adult lymphoma-associated hemophagocytic lymphohistiocytosis: a multicenter analysis of 326 patients

  2024cites this paper
• Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma

  2024cites this paper
• Follicular lymphoma research: an open dialogue for a collaborative roadmap

  2024cites this paper
• Outcome of extra-nodal follicular lymphoma affected by choice of induction chemoimmunotherapy and maintenance rituximab – real-world retrospective study

  2024cites this paper
• Outcomes of follicular lymphoma with leukemic phase in the modern era: results from a large multicenter study

  2024cites this paper
• Prognostic Significance of Interim PET/CT in the First-Line Treatment of Follicular Lymphoma Patients, a Single-Center Experience

  2024cites this paper
• In pursuit of a functional cure for follicular lymphoma.

  2024cites this paper
• Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients

  2024cites this paper
• Combining Total Metabolic Tumor Volume With Beta‐2‐Microglobulin Levels Predicts Outcomes in High‐Burden Follicular Lymphoma Patients

  2024cites this paper
• Effect of POD24 on the prognosis of follicular and other indolent B-cell non-hodgkin lymphomas

  2024cites this paper
• The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma

  2024cites this paper
• Follicular lymphoma treatment decisions: put GELF on the shelf?

  2024cites this paper
• Clinical-Demographic Profile, Prognostic Factors and Outcomes in Classic Follicular Lymphoma Stratified by Staging and Tumor Burden: Real-World Evidence from a Large Latin American Cohort

  2024cites this paper
• Bispecific antibodies for the treatment of hematologic malignancies: The magic is T-cell redirection.

  2024cites this paper
• High Ki-67 Expression Predicting a Risk Factor for the Progression of Disease within 24 Months and Microenvironment in Follicular Lymphoma

  2024cites this paper
• Time to lymphoma treatment within 24 months in ‘watch and wait’ follicular lymphoma is associated with inferior outcomes: A multicentre analysis

  2024cites this paper
• Proteomic Profiling Identifies Predictive Signatures for Progression Risk in Patients with Advanced-Stage Follicular Lymphoma

  2024cites this paper
• Impact of positive CD4 cells on event‐free survival in follicular lymphoma patients

  2024cites this paper
• Maximum disease diameter is associated with outcomes in stage II follicular lymphoma treated with radiation therapy alone

  2024cites this paper
• Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy

  2024cites this paper
• Cholecystocutaneous Fistula Associated with Edwardsiella tarda as a Result of Aggressive Lymphoma Development

  2024cites this paper
• Revisiting beta‐2 microglobulin as a prognostic marker in diffuse large B‐cell lymphoma

  2024cites this paper
• Efficacy and safety of MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trial

  2024cites this paper
• Diagnosis, management and follow‐up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

  2024cites this paper
• Early histological transformation of follicular lymphoma to diffuse large B‐cell lymphoma indicating adverse survival: A population‐based analysis and validation

  2024cites this paper
• Serum beta2-microglobulin acts as a biomarker for severity and prognosis in glioma patients: a preliminary clinical study

  2024cites this paper
• Infections and their prognostic significance before diagnosis of chronic lymphocytic leukemia, non-Hodgkin lymphoma, or multiple myeloma

  2024cites this paper
• Immunogenicity of COVID‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy

  2024cites this paper
• Utilizing Clinical Transformation Criteria for Prognostic Stratification in Follicular Lymphoma Prior to Initial Immunochemotherapy

  2024cites this paper
• Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients

  2024cites this paper
• Translational insights into the genetics and immunobiology of relapsed/refractory follicular lymphoma.

  2024cites this paper
• How Should We Risk Stratify and Tailor Therapy for Relapsed/Refractory Indolent Lymphoma?

  2024cites this paper
• 单中心85例初治滤泡淋巴瘤临床特征、预后分析及老年综合评估

  2024cites this paper
• The Role of Beta2-Microglobulin in Central Nervous System Disease

  2024cites this paper
• Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice

  2024cites this paper
• Treatment of follicular lymphoma with a focus on radiotherapy

  2024cites this paper
• Advancements in the Management of Follicular Lymphoma: A Comprehensive Review

  2024cites this paper
• High Ki67 index is associated with shorter progression free survival in patients with Follicular Lymphoma treated with frontline immunochemotherapy

  2024cites this paper
• 我如何治疗复发/转化滤泡性淋巴瘤

  2023cites this paper
• Reviewing the potential of probiotics, prebiotics and synbiotics: advancements in treatment of ulcerative colitis

  2023cites this paper
• Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study

  2023cites this paper
• Metabolic bulk volume from FDG PET as an independent predictor of progression-free survival in follicular lymphoma

  2023cites this paper